--- title: 'Clinical Daily Summary: What Happened on November 9, 2026' headline: Lilly’s Foundayo meets Phase III endpoint in sleep apnea description: Novartis’ pelacarsen lowered lipoprotein(a) without reducing cardiovascular events. Faeth reported mid-stage cancer data, and a report raised possible tumor concerns linked to pediatric gene therapies. url: https://thebench.bio/news/clinical/2026-11-09 topic: clinical date: '2026-11-09' covers: - '2026-11-09' date_published: '2026-11-09T12:02:10Z' date_modified: '2026-11-10T00:01:14Z' tags: - Clinical - Industry - Software sources: 13 publisher: TheBench.Bio --- # Clinical Daily Summary: What Happened on November 9, 2026 **Lilly’s Foundayo meets Phase III endpoint in sleep apnea** Novartis’ pelacarsen lowered lipoprotein(a) without reducing cardiovascular events. Faeth reported mid-stage cancer data, and a report raised possible tumor concerns linked to pediatric gene therapies. ## Today in brief Eli Lilly’s Foundayo reduced sleep-apnea measures over 52 weeks in adults with overweight or obesity, meeting the primary endpoint of a Phase III trial. [1] Novartis’ pelacarsen lowered lipoprotein(a) but did not change heart attack or stroke rates in a study presented at the American Heart Association meeting. [2] Faeth reported confirmed tumor responses in 12 of 36 evaluable patients with advanced or recurrent endometrial cancer treated with its PIKTOR-paclitaxel combination. [3] A report described evidence of a possible link between pediatric gene therapies and tumors. [4] ## Foundayo improved sleep-apnea measures in Phase III Lilly’s oral drug Foundayo met the primary endpoint in the Phase III ATTAIN-OSA study, lowering apnea-hypopnea index scores at 52 weeks in adults with overweight or obesity. [1] Among participants not using positive airway pressure, the index fell by 21.1 events per hour with Foundayo and 5.5 with placebo. [1] For participants using positive airway pressure, the reductions were 18.3 and 4.3 events per hour, respectively. [1] Participants taking Foundayo lost an average of 28 pounds, and the study also found reductions in hypoxic burden, inflammation and systolic blood pressure. [1] Gastrointestinal events were the most common adverse events. The overall safety profile was consistent with earlier Foundayo studies. [1] Lilly said it plans to seek FDA approval for moderate-to-severe obstructive sleep apnea in adults with overweight or obesity by the end of 2026. [1] ## Pelacarsen lowered lipoprotein(a) but did not cut cardiovascular events Pelacarsen lowered blood levels of lipoprotein(a), a cardiovascular risk marker, but did not change heart attack or stroke rates in a Novartis study. [2] The results were presented at the American Heart Association’s annual meeting. [2] ## Faeth reports responses with endometrial-cancer combination Faeth Therapeutics’ PIKTOR combination with paclitaxel produced confirmed tumor responses in 12 of 36 evaluable patients with advanced or recurrent endometrial cancer. [3] The single-arm Phase II study enrolled patients whose cancers had PAM-pathway mutations and progressed after platinum chemotherapy and a checkpoint inhibitor. [3] Median progression-free survival was 7.4 months, and 62% of patients had not progressed at six months. [3] Seven percent stopped treatment because of adverse events, and the study reported no drug-related deaths. [3] Faeth plans to advance the combination to Phase III but has not set a start date. [3] ## Also worth knowing - Nkarta reported preliminary NKX019 results in small autoimmune-disease studies. Five of six myositis patients had moderate or major muscle-strength responses, and six of seven systemic-sclerosis patients reached at least a 25% response on a composite measure. [5] - Johnson & Johnson said 11 of 15 patients on its pasritamig-JNJ-9401 combination had PSA reductions of at least 50% in an early prostate-cancer study. No grade 3 or worse treatment-related events were reported in that group. [6] - UCB reported week-24 ACR50 responses of 54.9% with bimekizumab and 43.8% with risankizumab in psoriatic arthritis, describing the comparison as exploratory. [7] - Insilico Medicine reported partial responses in four of 22 evaluable mesothelioma patients treated with its experimental TEAD inhibitor ISM6331. The company said it plans a randomized Phase 2a study in 2027, subject to the data. [8] - In a Phase II stiff-person syndrome trial, 21 of 26 patients improved their walking ability by at least 20%. The study had no control group and a median follow-up of 6.5 months. [9] - Bristol Myers Squibb reported that 43 adolescents completed the first 28 weeks of the SCOUT-HCM trial and received Camzyos through week 56. No participant’s left ventricular ejection fraction fell below 50%. [10] - Resistance training three times a week reduced lean-tissue loss and improved strength during 40 weeks of tirzepatide treatment in a randomized trial of 120 adults with overweight or obesity. [11] - Sanofi stopped development of Nurix’s Phase I STAT6 degrader SAR448272. The companies’ broader collaboration remains in place. [12] - Immunocore estimated two-year survival at 70% among 17 evaluable patients receiving brenetafusp with Kimmtrak for metastatic uveal melanoma. The comparison with Kimmtrak alone came from an earlier trial, not a randomized control group. [13] ## The day in numbers - **21.1 vs. 5.5 events per hour**: Reduction in apnea-hypopnea index with Foundayo versus placebo among participants not using positive airway pressure. [1] - **12 of 36**: Evaluable endometrial-cancer patients with a confirmed response to Faeth’s PIKTOR-paclitaxel combination. [3] - **7.4 months**: Median progression-free survival in Faeth’s Phase II endometrial-cancer study. [3] ## Also published - [Vir hepatitis D drug succeeds in first pivotal study](), BioPharma Dive - [Janux’s JANX011 T-Cell Engager Shows Deep B-Cell Depletion in Phase 1 Healthy Volunteer Study](), BioPharm International - [Therapeutic Immune Manipulation](), GEN - [Europe’s growing vector-borne disease threat: Are we keeping pace?](), pharmaphorum - [Effective Methods of Accurately Measuring Tumors](), Pharmaceutical Executive - [Translating Phase II success into Phase III readiness takes more than scale](), BioPharma Dive - [Novartis' pelacarsen fail raises questions for other drugs](), pharmaphorum - [OncoC4 announces positive Phase I/II findings for cesalatamig in NSCLC](), Clinical Trials Arena - [OCT New England 2026: Tackling the Patient Enrolment Crisis](), Clinical Trials Arena ## Sources 1. [AHA26: Lilly’s Foundayo benefits beyond weight loss in Phase III sleep apnoea win](), Clinical Trials Arena, 2026-11-09 2. [STAT+: Why the latest heart drug failures should make us all more skeptical of AI hype](), STAT Biotech, 2026-11-08 3. [Faeth’s combo posts mid-stage refractory endometrial cancer win](), Clinical Trials Arena, 2026-11-09 4. [STAT+: Gene therapy’s long-debated cancer risk materializes](), STAT Biotech, 2026-11-09 5. [Nkarta Autoimmune Disease Cell Therapy’s First Human Data Show Safety, Signs of Efficacy](), MedCity News, 2026-11-09 6. [J&J’s Dual-Antigen Bispecific Regimen Achieves 73% PSA Response in Advanced Prostate Cancer](), BioPharm International, 2026-11-09 7. [UCB Reports 24-Week Bimekizumab (Bimzelx) vs Risankizumab Data in PsA](), BioPharm International, 2026-11-09 8. [Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027](), Drug Discovery and Development, 2026-11-09 9. [CAR T-Cell Therapy Restores Mobility in Patients with Treatment-Resistant Stiff Person Syndrome](), Inside Precision Medicine, 2026-11-09 10. [BMS’s Camzyos shows continued benefit in paediatric oHCM at 56 weeks](), Clinical Trials Arena, 2026-11-09 11. [Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial](), Nature Medicine, 2026-11-09 12. [StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate](), GEN, 2026-11-09 13. [Immunocore doubles up on T-cell engagers in eye cancer](), European Biotechnology, 2026-11-09 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: [4]: [5]: [6]: [7]: [8]: [9]: [10]: [11]: [12]: [13]: